Blog

  • NASA Finds Signs of Ancient Microbial Life in a Rock on Mars

    NASA Finds Signs of Ancient Microbial Life in a Rock on Mars

    Did Mars once harbor life? 

    NASA’s Perseverance rover’s latest discovery of potential biosignatures from a rock formation named Cheyava Falls might have just answered that question, hinting that some form of life could have been hidden…

    Continue Reading

  • Resonant Memory: Works by Steina and Woody Vašulka – Events

    Resonant Memory: Works by Steina and Woody Vašulka – Events

    Robyn Farrell is Senior Curator and Director of Curatorial Affairs at The Kitchen in New York where she oversees the exhibition, performance, and publication program. Her research interests include conceptual art and the moving image, emerging…

    Continue Reading

  • Madison Beer announces ‘Locket’ – The Music Universe

    Madison Beer announces ‘Locket’ – The Music Universe

    The album will be available on January 16th

    Platinum-selling multi-hyphenate creative force Madison Beer announces her next studio album, Locket, out via Epic Records on January 16th. Written and co-produced by Beer, the album also features…

    Continue Reading

  • Just a moment…

    Just a moment…

    Continue Reading

  • Just a moment…

    Just a moment…

    Continue Reading

  • Just a moment…

    Just a moment…

    Continue Reading

  • TechnipFMC Announces Quarterly Dividend and Additional $2 Billion Share Repurchase Authorization

    TechnipFMC Announces Quarterly Dividend and Additional $2 Billion Share Repurchase Authorization

    NEWCASTLE & HOUSTON, October 22, 2025 — TechnipFMC plc (NYSE: FTI) today announced that its Board of Directors has authorized and declared a quarterly cash dividend of $0.05 per share, payable on December 3, 2025 to shareholders of record as of the close of business on the New York Stock Exchange on November 18, 2025, which is also the ex-dividend date.

    The Board has also authorized additional share repurchases of up to $2 billion. Together with the remaining balance under the existing program, the Company is now authorized to repurchase shares of up to $2.3 billion, representing nearly 16 percent of the Company’s outstanding shares at the closing price on October 21, 2025. 

    Doug Pferdehirt, TechnipFMC’s Chair and CEO, stated, “Since the initial share repurchase authorization in July 2022, the Company has returned more than $1.6 billion to shareholders through stock repurchases and dividends. This significant increase to the share authorization exemplifies our confidence in the outlook, as well as our commitment to maximize shareholder value.”

    The Company expects to repurchase shares from time to time through open market purchases, privately negotiated transactions, Rule 10b5-1 plans, and any other means in accordance with applicable securities laws. The share repurchase program does not obligate the Company to repurchase shares and may be suspended or discontinued at any time at the Company’s discretion.

    Important Information for Investors and Securityholders

    Forward-Looking Statement

    This release contains “forward-looking statements” as defined in Section 27A of the United States Securities Act of 1933, as amended, and Section 21E of the United States Securities Exchange Act of 1934, as amended. The words “expect,” “believe,” “estimated,” and other similar expressions are intended to identify forward-looking statements, which are generally not historical in nature. Such forward-looking statements involve significant risks, uncertainties and assumptions that could cause actual results to differ materially from our historical experience and our present expectations or projections. For information regarding known material factors that could cause actual results to differ from projected results, including our assumptions and projections regarding the announced share repurchase program, please see our risk factors set forth in our filings with the United States Securities and Exchange Commission, which include our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. We caution you not to place undue reliance on any forward-looking statements, which speak only as of the date hereof. We undertake no obligation to publicly update or revise any of our forward-looking statements after the date they are made, whether as a result of new information, future events or otherwise, except to the extent required by law.

     

    ###

    About TechnipFMC

    TechnipFMC is a leading technology provider to the traditional and new energy industries, delivering fully integrated projects, products, and services. 

    With our proprietary technologies and comprehensive solutions, we are transforming our clients’ project economics, helping them unlock new possibilities to develop energy resources while reducing carbon intensity and supporting their energy transition ambitions. 

    Organized in two business segments — Subsea and Surface Technologies — we will continue to advance the industry with our pioneering integrated ecosystems (such as iEPCI™, iFEED™ and iComplete™), technology leadership and digital innovation.

    Each of our approximately 21,000 employees is driven by a commitment to our clients’ success, and a culture of strong execution, purposeful innovation, and challenging industry conventions.

    TechnipFMC uses its website as a channel of distribution of material company information. To learn more about how we are driving change in the industry, go to www.TechnipFMC.com and follow us on X @TechnipFMC. 

    Contacts

    Investor relations
    Matt Seinsheimer
    Senior Vice President, Investor Relations and Corporate Development
    Tel: +1 281 260 3665
    Email: Matt Seinsheimer

    James Davis
    Director, Investor Relations
    Tel: +1 281 260 3665
    Email: James Davis

    Media relations
    Mendi Head
    Public Relations and Media Relations
    Tel: +1 346 297 8392
    Email: Mendi Head 

    Continue Reading

  • PacBio to Report Third Quarter 2025 Financial Results on November 5, 2025

    PacBio to Report Third Quarter 2025 Financial Results on November 5, 2025

    MENLO PARK, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its third quarter 2025 financial results on Wednesday, November 5, 2025, at 4:30 pm Eastern Time.

    The call will be webcast and may be accessed at PacBio’s website at https://investor.pacificbiosciences.com/.

    Date: Wednesday, November 5, 2025, at 4:30 pm ET (1:30 pm PT)
    Listen live via internet or replay: https://investor.pacificbiosciences.com/
    Toll-free: 1-888-349-0136
    International: 1-412-317-0459

    If using the dial-in option, please join the call ten minutes before the start time using the appropriate number above and ask to join the “PacBio Q3 Earnings Call.”

    About PacBio

    PacBio (NASDAQ: PACB) is a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. Our products and technologies, which include our HiFi long-read sequencing, address solutions across a broad set of research applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. For more information, please visit www.pacb.com and follow @PacBio.

    PacBio products are provided for Research Use Only. Not for use in diagnostic procedures.

    Contacts

    Investors:
    Jim Gibson
    ir@pacb.com

    Media:
    pr@pacb.com

    Continue Reading

  • The Story Behind Ireland’s First Win Over the All Blacks » allblacks.com

    The Story Behind Ireland’s First Win Over the All Blacks » allblacks.com

    Playing the All Blacks in Chicago again on Saturday week has fond memories for Irish rugby fans, as their first game resulted in Ireland’s first win over New Zealand.

    Donnacha Ryan played in the 40-29 win and told The Irish…

    Continue Reading

  • Real-World Studies Reinforce Axi-Cel and Liso-Cel as Effective LBCL Treatments

    Real-World Studies Reinforce Axi-Cel and Liso-Cel as Effective LBCL Treatments

    How have the FDA approvals of axi-cel and liso-cel affected the LBCL treatment paradigm?

    Five years ago, irrespective of relapse status or primary refractoriness, the standard of care would have been salvage platinum-containing chemotherapy…

    Continue Reading